Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: cambier n. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.
Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N. Renaud L, et al. Among authors: cambier n. Am J Hematol. 2019 Jan;94(1):E24-E27. doi: 10.1002/ajh.25328. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30358899 Free article. No abstract available.
Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G; AdheRMC Investigators. Huguet F, et al. Among authors: cambier n. Br J Haematol. 2019 Dec;187(5):615-626. doi: 10.1111/bjh.16145. Epub 2019 Aug 8. Br J Haematol. 2019. PMID: 31394591 Free article.
Familial myeloid malignancies with germline TET2 mutation.
Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T, Fournier E, Nibourel O, Roche-Lestienne C, Huet G, Beauvais D, Berthon C, Cambier N, Quesnel B, Preudhomme C. Duployez N, et al. Among authors: cambier n. Leukemia. 2020 May;34(5):1450-1453. doi: 10.1038/s41375-019-0675-6. Epub 2019 Dec 11. Leukemia. 2020. PMID: 31827242 No abstract available.
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Heiblig M, Duployez N, Marceau A, Lebon D, Goursaud L, Plantier I, Stalnikiewich L, Cambier N, Balsat M, Fossard G, Labussière-Wallet H, Barraco F, Ducastelle-Lepretre S, Sujobert P, Huet S, Hayette S, Ghesquières H, Thomas X, Preudhomme C. Heiblig M, et al. Among authors: cambier n. Cancers (Basel). 2021 Apr 29;13(9):2156. doi: 10.3390/cancers13092156. Cancers (Basel). 2021. PMID: 33947035 Free PMC article.
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Verstovsek S, et al. Among authors: cambier n. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. Blood Adv. 2023. PMID: 37042865 Free PMC article.
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, Martino B, Pezzutto A, Carli G, De Muro M, Luciani S, McMullin MF, Cambier N, Marolleau JP, Mesa RA, Tibes R, Pancrazzi A, Gesullo F, Bettica P, Manzoni S, Di Tollo S. Rambaldi A, et al. Among authors: cambier n. Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11. Leukemia. 2020. PMID: 32047238 Free PMC article. Clinical Trial. No abstract available.
Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.
Charpentier A, Lebreton A, Rauch A, Bauters A, Trillot N, Nibourel O, Tintillier V, Wemeau M, Demory JL, Preudhomme C, Jude B, Lecompte T, Cambier N, Susen S. Charpentier A, et al. Among authors: cambier n. Haematologica. 2016 Sep;101(9):e365-8. doi: 10.3324/haematol.2016.144279. Epub 2016 May 31. Haematologica. 2016. PMID: 27247323 Free PMC article. No abstract available.
56 results